The short version of melanotan-2 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-21 and is reviewed periodically as new material appears.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
About 2/3 of chiral products produced on large industrial scale are already made using biocatalysis. In the manufacture of fine chemicals, enzymes represent the single most important technology for radical cost reductions. This is particularly the case in the synthesis of molecules with chiral centres. Here, it is possible to substitute the formation of a salt with a chiral compound, such as (+)-α-phenylethylamine, crystallization, salt breaking and recycling of the chiral auxiliary, resulting in a theoretical yield of not more than 50%, with a one step, high yield reaction under mild conditions that results in a product with a very high enantiomeric excess (ee). An example is AstraZeneca's blockbuster drug Crestor (rosuvastatin).
A κ-opioid receptor agonist, or simply KOR agonist or kappa agonist, is a drug which acts as an agonist of the κ-opioid receptor (KOR), the target of the endogenous dynorphin peptides such as dynorphin A and one of several types of opioid receptors. They can variably produce hallucinogenic effects, pro-depressive and dysphoric effects, sedation, analgesic effects, antipruritic (anti-itch) effects, and anti-addictive effects, among others. Due to their various effects, KOR agonists are used for a variety of medical uses and for other purposes. Salvinorin A is a highly potent and selective KOR agonist and hallucinogen found in Salvia divinorum (diviner's sage) which has been used as an entheogen by the Mazatec people of Mexico and as a recreational drug elsewhere. The psychoactive and other effects of salvinorin A have been evaluated in clinical studies. The non-selective opioid receptor antagonist naltrexone blocks the effects of salvinorin A. Synthetic analogues with greater potency and/or duration include salvinorin B methoxymethyl ether (2-MMSB) and salvinorin B ethoxymethyl ether (2-EMSB). The irreversible G protein-biased agonist RB-64 (22-thiocyanatosalvinorin A) has unknown psychoactivity. Nalorphine (N-allylnormorphine; Lethidrone; Nalline) was an early opioid antagonist used to reverse opioid overdose which acts as a dual μ-opioid receptor (MOR) agonist–antagonist and KOR agonist and was superseded by other drugs like naloxone due to producing dysphoria and hallucinogenic effects among other drawbacks.
Glenn experienced no such difficulties, and it was determined that microgravity did not affect the natural swallowing process, which is enabled by the peristalsis of the esophagus. Astronauts in later Mercury missions (1959–1963) disliked the food that was provided. They ate bite-sized cubes, freeze-dried powders, and tubes of semiliquids. The astronauts found it unappetizing, experienced difficulties in rehydrating the freeze-dried foods, and did not like having to squeeze tubes or collect crumbs. Prior to the mission, the astronauts were also fed low residual launch-day breakfasts to reduce the chances that they would defecate in flight.
=== DNA damage === Arsenic is reported to cause DNA modifications such as aneuploidy, micronuclei formation, chromosome abnormality, deletion mutations, sister chromatid exchange and crosslinking of DNA with proteins. It has been demonstrated that arsenic does not directly interact with DNA and it is considered a poor mutagen, but instead, it helps mutagenicity of other carcinogens. For instance, a synergistic increase in the mutagenic activity of arsenic with UV light has been observed in human and other mammalian cells after exposing the UV-treated cells to arsenic. A series of experimental observations suggest that the arsenic genotoxicity is primarily linked to the generation of reactive oxygen species (ROS) during its biotransformation. The ROS production is able to generate DNA adducts, DNA strand breaks, crosslinks and chromosomal aberrations. The oxidative damage is caused by modification of DNA nucleobases, in particular 8-oxoguanine (8-OHdG) which leads to G:C to T:A mutations. Inorganic arsenic can also cause DNA strand break even at low concentrations.
Sources: en.wikipedia.org
=== Weighted boots === Weighted boots of several styles may be used if the diver will be working heavy. Some are in the form of clogs which strap on over the boots, and others use lead inner soles. Ankle weights are also an option, but less comfortable. These weights give the diver better stability when working upright on the bottom, which can significantly improve productivity for some kinds of work.
==== Well drilling ==== Some of the purposes of well drilling include: personal use, measurements of hydraulic head, aquifer testing, and remediation of various contaminants. "Pump-and-treat" is particularly effective for removing LNAPLs floating above the water table. Efforts must be taken during well drilling to minimize disturbances that might cause further infiltration of DNAPLs into the subsurface. It is easy to unknowingly drill through a DNAPL pool, causing the pool to drain down further into the aquifer.
Allan Maxam and Walter Gilbert published a DNA sequencing method in 1977 based on chemical modification of DNA and subsequent cleavage at specific bases. Also known as chemical sequencing, this method allowed purified samples of double-stranded DNA to be used without further cloning. This method's use of radioactive labeling and its technical complexity discouraged extensive use after refinements in the Sanger methods had been made. Maxam-Gilbert sequencing requires radioactive labeling at one 5' end of the DNA and purification of the DNA fragment to be sequenced. Chemical treatment then generates breaks at a small proportion of one or two of the four nucleotide bases in each of four reactions (G, A+G, C, C+T). The concentration of the modifying chemicals is controlled to introduce on average one modification per DNA molecule. Thus a series of labeled fragments is generated, from the radiolabeled end to the first "cut" site in each molecule. The fragments in the four reactions are electrophoresed side by side in denaturing acrylamide gels for size separation. To visualize the fragments, the gel is exposed to X-ray film for autoradiography, yielding a series of dark bands each corresponding to a radiolabeled DNA fragment, from which the sequence may be inferred. This method is mostly obsolete as of 2023.
This remained Knoxville's style of government until the early 20th century, though the city's charter was amended in 1838 to allow for popular election of mayor as well. In January 1816, Knoxville's newly elected Board of Aldermen chose Judge Thomas Emmerson (1773–1837) as the city's first mayor. With the exceptions of the years 1802, 1807, 1811 and 1812, Knoxville remained the capital of Tennessee until 1817 when the state legislature was moved to Murfreesboro.
Prescientific forms of medicine, now known as traditional medicine or folk medicine, remain commonly used in the absence of scientific medicine and are thus called alternative medicine. Alternative treatments outside of scientific medicine with ethical, safety and efficacy concerns are termed quackery or being based on fringe science.
Sources: en.wikipedia.org
=== Off-label drugs === Alcohol (over-the-counter self-medication) – GABAA receptor positive allosteric modulator Atypical antipsychotics (e.g., olanzapine, quetiapine) – monoamine receptor modulators Benzodiazepines (e.g., alprazolam, chlordiazepoxide, clonazepam, diazepam, lorazepam, oxazepam) – GABAA receptor positive allosteric modulators Beta blockers (e.g., atenolol, propranolol) – β-adrenergic receptor antagonists Bupropion (Wellbutrin) – norepinephrine–dopamine reuptake inhibitor (NDRI) and nicotinic acetylcholine receptor negative allosteric modulator Cannabidiol (CBD) – cannabinoid receptor modulator and other actions, found in cannabis Gabapentinoids (e.g., gabapentin, pregabalin) – α2δ subunit-containing voltage-dependent calcium channel blockers Monoamine oxidase inhibitors (MAOIs) (e.g., phenelzine, selegiline, tranylcypromine) NMDA receptor antagonists (e.g., ketamine) Other anticonvulsants (besides gabapentinoids) (e.g., topiramate, valproic acid, tiagabine) Psychostimulants (e.g., amphetamine, methylphenidate) Selective serotonin reuptake inhibitors (SSRIs) (non-licensed) (e.g., citalopram, fluoxetine) Serotonin–norepinephrine reuptake inhibitors (SNRIs) (non-licensed) (e.g., desvenlafaxine, duloxetine) Serotonin 5-HT1A receptor agonists (e.g., buspirone) Tricyclic antidepressants (TCAs) (e.g., clomipramine, imipramine)
==== Alemtuzumab ==== Alemtuzumab (Campath-1H) is an anti-CD52 humanized IgG1 monoclonal antibody indicated for the treatment of fludarabine-refractory chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma, peripheral T-cell lymphoma and T-cell prolymphocytic leukemia. CD52 is found on >95% of peripheral blood lymphocytes (both T-cells and B-cells) and monocytes, but its function in lymphocytes is unknown. It binds to CD52 and initiates its cytotoxic effect by complement fixation and ADCC mechanisms. Due to the antibody target (cells of the immune system), common complications of alemtuzumab therapy are infection, toxicity and myelosuppression.
==== K ==== Kashk – is used in a large family of foods found in Lebanese, Palestinian, Egyptian, Kurdish, Iranian, and Central Asian cuisine. It is made from drained sour milk or yogurt by forming it and letting it dry. It can be made in a variety of forms, including rolled into balls, sliced into strips, and formed into chunks.
Keepers should be careful of the combination of light and heat radiated from composite UV‑A and UV‑B lamps; typical lamps emit high levels of UV‑A with low levels of UV‑B that are often have different fixed strengths at different wavelengths that are difficult to adjust to meet different reptiles' metabolic needs. A better strategy is to use separate lamps for separate UV bands so that keepers can place and control the lamps' intensity for best animal health.
=== Exploration === In 1497 Bristol was the starting point for John Cabot's voyage of exploration to North America. For many years Bristol merchants had bought freeze-dried cod, called stockfish, from Iceland for consumption in England. However, the Hanseatic League, which was trying to control North Atlantic trade at this time, sought to cut off supplies to English merchants. It has often been suggested that this drove Bristol's merchants to look West for new sources of cod fish. On the other hand, while Bristol merchants did largely abandon Iceland in the late-15th century, Hull merchants continued to trade there. Moreover, recent research has shown that England's fisheries off Iceland actually grew significantly from the 1490s, albeit the centre for this activity shifted from Bristol to East Anglia. This makes it hard to sustain the argument that Bristol merchants were somehow 'pushed out' of Iceland. In 1481 two local men, Thomas Croft and John Jay, sent off ships looking for the mythical island of Hy-Brasil. There was no mention of the island being discovered but Croft was prosecuted for illegal exports of salt, on the grounds that, as a customs officer, he should not have engaged in trade. Professor David Beers Quinn, whose theories form the basis for a variety of popular histories, suggested that the explorers may have discovered the Grand Banks off Newfoundland, waters rich in cod. John Cabot was sponsored by Henry VII on his voyage in 1497, looking for a new route to the Orient.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.